Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Benzamides
  • Gastrointestinal Stromal Tumors
  • Piperazines
  • Pyrimidines

abstract

  • The scores generated were effective in stratifying the risk of GIST recurrence in patient populations treated with adjuvant imatinib. Patients with nongastric GIST with a high mitotic count are at a particularly high risk for recurrence.

publication date

  • August 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4209960

Digital Object Identifier (DOI)

  • 10.1002/cncr.28669

PubMed ID

  • 24737415

Additional Document Info

start page

  • 2325

end page

  • 33

volume

  • 120

number

  • 15